The quick answer
What does an Lp(a) result tell you?
Lp(a) is an LDL-like particle with an extra inherited protein called apolipoprotein(a). A higher concentration can add to the lifelong risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis.See reference ,See reference ,See reference
It is usually stable, causes no symptoms and is not included in a standard cholesterol panel. The result changes risk assessment; it does not diagnose plaque or valve disease by itself.
Six useful takeaways
Test at least once in adulthood
The 2026 ACC/AHA guideline now recommends one adult measurement for cardiovascular risk assessment.
The level is mostly inherited
Diet and exercise have little predictable effect on Lp(a), although both still matter for overall risk.
Units are not directly interchangeable
nmol/L estimates particle concentration; mg/dL measures mass. There is no safe universal conversion.
Risk rises continuously
The low, intermediate and high bands are practical decision aids, not biological cliff edges.
A high result is actionable
It can justify closer attention to LDL-C, ApoB, blood pressure, glucose, smoking and family screening.
Dedicated treatment evidence is unfinished
Lp(a)-targeted drugs can lower the number in trials, but cardiovascular-outcome results are still pending.
What it measures
An LDL-like particle with an inherited protein tail
Each Lp(a) particle contains one ApoB-bearing LDL-like particle joined to apolipoprotein(a). The LPA gene strongly influences both how much Lp(a) is produced and the size of the apolipoprotein(a) component.See reference ,See reference
Lp(a) is not the same as LDL-C or ApoB. LDL-C measures cholesterol cargo. ApoB estimates the total number of atherogenic particles. Lp(a) isolates one inherited particle type with additional risk information.
Understanding your result
Read the unit first, then the risk category
The National Lipid Association uses parallel risk bands for the two reporting systems. These bands describe Lp(a)-attributable risk; they are not a diagnosis and do not replace an absolute cardiovascular risk assessment.See reference
| Category | Particle concentration | Mass concentration |
|---|---|---|
| Low | <75 nmol/L | <30 mg/dL |
| Intermediate | 75–<125 nmol/L | 30–<50 mg/dL |
| High | ≥125 nmol/L | ≥50 mg/dL |
Risk does not suddenly appear at 125 nmol/L or 50 mg/dL. Lp(a) risk rises across the distribution, while age, blood pressure, smoking, diabetes, LDL-C, ApoB, kidney health and existing disease change the absolute meaning of the result.
Have an Lp(a) result?
Upload your blood work to understand Lp(a) beside ApoB, LDL-C, non-HDL-C, triglycerides, glucose and your previous results.
LongevityMate provides educational context, not diagnosis or personalised medical advice.
Units and conversion
Why nmol/L and mg/dL cannot be cleanly converted
nmol/L
How many particles?
Molar concentration is designed to reflect the number of Lp(a) particles in a litre of blood and is generally preferred for standardized reporting.
mg/dL
How much particle mass?
Mass concentration weighs Lp(a) material. People inherit differently sized apolipoprotein(a), so equal particle counts can have different mass.
Do not multiply by 2.5 and treat the result as exact
A rough population-level relationship appears in some educational material, but the European consensus FAQ does not recommend one conversion factor for individual results. Compare the original number with guidance written for the same unit.See reference ,See reference ,See reference
Practical next steps
My Lp(a) is high—what should I do next?
A high result is useful information, not an emergency by itself. The best response is to verify the measurement, calculate the wider risk and reduce the risks that can be changed.
- 1
Verify the unit and assay
Read the exact unit on the report. Do not compare a value in nmol/L with an internet threshold in mg/dL or use a fixed conversion calculator.
- 2
Place it in the full risk picture
Review LDL-C, ApoB, non-HDL-C, blood pressure, diabetes, smoking, kidney health, family history and any existing artery or valve disease.
- 3
Ask whether family testing is appropriate
A high result is strongly inherited. First-degree relatives may benefit from testing, especially when premature cardiovascular disease runs in the family.
- 4
Act on what is modifiable
A clinician can decide whether LDL-C and ApoB should be lowered more intensively and help address blood pressure, glucose, smoking and other risks.
Seek urgent medical help for chest pressure, severe shortness of breath, fainting or stroke-like symptoms. Lp(a) itself usually causes no symptoms, so urgent symptoms should never be explained away by a blood-test result.
Why it matters
Lp(a) adds inherited artery and aortic-valve risk
Lp(a) carries cholesterol into artery walls like other ApoB-containing particles and also transports oxidized phospholipids. Genetic, observational and mechanistic evidence supports Lp(a) as a causal contributor to atherosclerotic cardiovascular disease and calcific aortic valve stenosis.See reference ,See reference
Artery disease
Higher lifelong exposure is linked with coronary disease, heart attack, ischaemic stroke and peripheral artery disease.
Aortic valve stenosis
Lp(a) is also linked with calcification and narrowing of the aortic valve, a risk not captured by LDL-C alone.
Family risk
Because the concentration is strongly inherited, one high result can identify a reason to test close relatives.
A high Lp(a) concentration does not tell you whether plaque or valve narrowing is already present. It changes probability and prevention decisions; imaging, symptoms and clinical assessment answer different questions.
Testing and repeat timing
Usually one non-fasting blood test—sometimes a repeat
Sample
Serum or plasma from a standard venous blood draw.
Fasting
Usually unnecessary. Follow instructions for other tests collected at the same time.
Availability
Not normally included in the standard lipid panel and may need to be ordered separately.
Routine timing
At least once in adulthood; serial testing is unnecessary for most stable results.
The Royal College of Pathologists of Australasia accepts a non-fasting sample and recommends recording fasting status. Its current entry lists Lp(a) as non-MBS rebatable, so Australian access and out-of-pocket cost can vary.See reference
When might repeating Lp(a) be useful?
- The first result is close to a risk or treatment decision boundary.
- The repeat uses a better standardized assay or clarifies an unexpected unit.
- Pregnancy, menopause transition, significant inflammation, thyroid disease or kidney disease may have shifted the result.
- A clinician is monitoring an intervention known to affect Lp(a) or a clinical trial.
What affects Lp(a)
Genes dominate, but the result is not perfectly frozen
Lp(a) is substantially more genetically determined than LDL-C, triglycerides or glucose. This is why one adult result is usually informative for life and why a person can have a high value despite healthy habits.See reference ,See reference ,See reference
Strongest influence
- Inherited variation in the LPA gene
- Apolipoprotein(a) particle size
- Family ancestry and inherited distribution
Can cause meaningful variation
- Pregnancy and the menopause transition
- Kidney disease or nephrotic syndrome
- Hypothyroidism and some inflammatory states
- Assay method, calibration and biological variation
Population distributions differ across ancestry groups, but risk should not be dismissed or amplified using race alone. The result, assay and the person’s complete cardiovascular context remain more useful than a stereotype.
Treatment and risk reduction
The most proven strategy is to reduce total risk
Healthy eating, physical activity, not smoking, sleep and weight management usually do not lower inherited Lp(a) substantially. They remain valuable because cardiovascular events depend on the combined exposure to Lp(a), other ApoB particles, blood pressure, glucose and many other factors.
| Option | Effect on Lp(a) | What is actually established |
|---|---|---|
| Lifestyle | Usually little direct change | Can improve blood pressure, glucose, fitness and overall cardiovascular risk. |
| Statins | Usually unchanged or modestly higher | Lower LDL-C and ApoB and reduce cardiovascular events; high Lp(a) is not a reason to stop them. |
| PCSK9-targeted treatment | Modest average reduction | Primarily prescribed for LDL-C indications. This includes the first oral PCSK9 inhibitor approved in the US in July 2026. The Lp(a)-specific outcome question remains separate. |
| Lipoprotein apheresis | Large temporary reduction | Invasive and reserved for narrowly defined very-high-risk situations; eligibility varies by country. |
| Lp(a)-targeted RNA medicines | Large reductions in trials | Investigational at the research cutoff; lowering the laboratory value has not yet established an approved cardiovascular-outcome indication. |
Phase 3 cardiovascular-outcome trials are testing pelacarsen and olpasiran. At the July 28, 2026 cutoff, the registries did not provide completed outcome evidence that a dedicated Lp(a) reduction prevents events. The first approved oral PCSK9 inhibitor is an LDL-C treatment, not an Lp(a)-specific outcome therapy.See reference ,See reference ,See reference ,See reference
Common mistakes
Six interpretations that can mislead you
Using one conversion factor
Lp(a) particles differ in size. A universal mg/dL-to-nmol/L formula can move a result into the wrong risk category.
Calling 75 nmol/L and 75 mg/dL equivalent
The numbers look alike but measure different properties. Always keep the original unit attached.
Assuming a healthy lifestyle makes testing pointless
Lp(a) is mostly inherited and can be high despite excellent habits and an otherwise reassuring lipid panel.
Trying to treat the number with unproven supplements
A supplement-induced laboratory change is not proof that cardiovascular outcomes improve, and products can create side effects or interactions.
Stopping a statin because it does not lower Lp(a)
Statins reduce LDL-C and cardiovascular risk. A high Lp(a) result can make control of other atherogenic particles more important, not less.
Treating high Lp(a) as a diagnosis
It raises risk but does not prove plaque, a blocked artery or aortic valve stenosis, and it cannot predict when an event will occur.
Evidence and limitations
What Lp(a) can—and cannot—tell you
| Claim | Evidence | Important boundary |
|---|---|---|
| Lp(a) is substantially inherited. | Strong | Concentration can still shift with physiology, disease and assay method. |
| Higher lifelong Lp(a) contributes causally to ASCVD. | Strong | A single result does not calculate absolute risk or show existing plaque. |
| Lp(a) contributes to calcific aortic valve stenosis. | Strong | The blood test does not diagnose valve narrowing. |
| One adult measurement is useful. | Guideline recommended | Some people need a repeat because of borderline results or changing conditions. |
| A fixed unit conversion is accurate. | Not supported | Particle size and assay differences make individual conversion unreliable. |
| Lowering Lp(a) with a new targeted drug prevents events. | Not yet established | Outcome trials must show benefit, not only a lower laboratory number. |
The result is most useful beside ApoB and the full risk picture
Lp(a) identifies a mostly inherited source of risk. ApoB estimates total atherogenic particle burden. LDL-C and non-HDL-C describe cholesterol mass. Blood pressure, glucose, smoking, kidney health, family history and established disease change absolute risk and what should happen next.